167091-96-5

Usage

Uses

Used in Pharmaceutical Industry:
[4-(4-fluorophenoxy)phenyl]methanol is used as a building block for the synthesis of various pharmaceuticals. Its unique structure and the presence of a fluorine atom make it an interesting target for medicinal chemistry and drug discovery research.
Used in Agrochemical Industry:
In the agrochemical industry, [4-(4-fluorophenoxy)phenyl]methanol is utilized as a starting material for the development of new agrochemicals, contributing to the creation of innovative products for agricultural applications.
Used in Organic Chemistry:
[4-(4-fluorophenoxy)phenyl]methanol serves as a valuable building block in the field of organic chemistry, enabling the synthesis of a wide range of fine chemicals with diverse applications.
Used in Material Science:
With its unique properties, [4-(4-fluorophenoxy)phenyl]methanol has potential applications in the development of new materials, where its fluorine-containing structure may offer advantages in terms of reactivity, stability, or other material properties.
Used as a Reagent in Organic Transformations:
In addition to its applications in various industries, [4-(4-fluorophenoxy)phenyl]methanol can also be employed as a reagent in organic transformations, facilitating specific chemical reactions and contributing to the synthesis of complex organic molecules.

Upstream product

• 371-41-5 4-Fluorophenol 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 83642-03-9 4-(4-fluorophenoxy)benzyl bromide 
• 1380427-33-7 2-((4-(4-fluorophenoxy)benzyl)thio)-5-((2-methoxypyrimidin-5-yl)methyl)pyrimidin-4(1H)-one 
• 1380427-34-8 2-[({4-[(4-fluorophenyl)oxy]phenyl}methyl)thio]-1-methyl-5-{[2-(methyloxy)-5-pyrimidinyl]methyl}-4(1H)-pyrimidinone 
• 1380427-35-9 1-ethyl-2-[({4-[(4-fluorophenyl)oxy]phenyl}methyl)thio]-5-{[2-(methyloxy)-5-pyrimidinyl]methyl}-4(1H)-pyrimidinone 
• 868146-52-5 4-fluorophenoxybenzyl acetate 

Relevant academic research and scientific papers

Synthesis and Structure-Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6 S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine (PA-824)

Novel extended side chain nitroimidazooxazine analogues featuring diverse linker groups between two aryl rings were studied as a potential strategy to improve solubility and oral activity against chronic infection by Mycobacterium tuberculosis. Both lipop

PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema (I).

THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, C1-4alkyl, C1-4alkoxy, CF3 and OCF3; -Y- represents formula (IA) R3 represents hydrogen, fluoro, chloro or C1-4alkyl; R4a and R4b each independently represent hydrogen, C1-4alkyl, C1-4alkoxy, CF3 or halo; and R5 represents a group Z-X; wherein Z is absent or represents (CH2)2 or O; and X represents formula (IB) wherein: J and L both represent CH, or one of J and L represents CH and the other represents N; when both J and L represent CH, R6 represents hydrogen, halo, CF3, C1-4alkyl or C1-4alkoxy in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, OCF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; or when one of J or L represents N, R6 represents hydrogen or halo in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; and R8 and R9 are independently selected from hydrogen and C1-4alkyl; or salts thereof which activate soluble guanylate cyclase (sGC), pharmaceutical compositions containing them, their use in medicine, and processes for their preparation.

2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS

Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, CF3, C1-4alkyl and allyl; Y represents (II), (III), (IV) or (V) wherein R3 represents CF3 or C1-4alkyl; and R3a represents CF3 or C1-4alkyl.

PYRAZOLES AS HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2 INHIBITORS

A class of novel pyrazoles is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock

Pyrazoles as human non-pancreatic secretory phospholipase A2 inhibitors

A class of novel pyrazoles is disclosed together with the use of such compounds for inhibiting sPLA2mediated release of fatty acids for treatment of conditions such as septic shock.